Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balixafortide + eribulin versus eribulin in HER2-negative recurrent or metastatic breast cancer
2018-004211-42Phase 3Terminated
- Sponsor
- Polyphor
- Start
- Mar 2019
- Modality
- Small Molecules, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Balixafortide + eribulin with Eribulin monotherapy (2 arms). Primary endpoints: Progression-free survival and Objective response rate. Started Mar 2019; status: terminated.
02
Drugs
balixafortideeribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-004211-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004211-42.